# Nymox Pharmaceutical Corporation (NYMXF)

> Healthcare · BS · Reports in USD

Fundamental indicators from Sponda, adjusted for inflation.

[HTML version](https://sponda.capital/en/NYMXF/fundamentals)

## Annual figures

| Year | Revenue (M) | Net Inc. (M) | FCF (M) | Debt (M) | Equity (M) |
| --- | --- | --- | --- | --- | --- |
| 2024 | $ 0 | $ -1.65M | $ -753.6K | N/A | $ -6.78M |
| 2023 | $ 0 | $ -9.56M | $ -4.40M | $ 750.0K | $ -3.17M |
| 2022 | $ 0 | $ -7.35M | $ -5.58M | $ 173.0K | $ -482.0K |
| 2021 | $ 0 | $ -7.26M | $ -6.10M | $ 391.0K | $ 83.0K |

Columns not available in this view: annualPriceMultiples, dividends. They require live market data and are shown on the HTML page instead.

## Leverage and liquidity

| Indicator | Value |
| --- | --- |
| Liabilities / Eq | -1.10 |
| Current Ratio | 0.09 |

## Other views

- [Metrics](https://sponda.capital/en/NYMXF.md)
- [Charts](https://sponda.capital/en/NYMXF/charts.md)
- [Compare](https://sponda.capital/en/NYMXF/compare.md)
- [Indicator definitions](https://sponda.capital/en/screener.md)

Data as of 2026-08-29.